Scholarlink

<p>In the pursuit of therapeutic agents for Alzheimer’s disease (AD), this study employed a molecular hybridization strategy to design and synthesize substituted cinnamoyl piperidinyl acetates. A total of 17 novel derivatives were evaluated for their inhibitory effects against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), key enzymes implicated in AD pathogenesis. Notably, compound <b>5b</b>, featuring a 2-chloro substitution, emerged as the most potent AChE inhibitor (IC<sub>50</sub> = 19.74 ± 0.96 µM), while compound <b>5q</b>, possessing a 4-ethoxy-3-methoxy moiety, demonstrated superior BChE inhibition (IC<sub>50</sub> = 13.49 ± 0.44 µM). Kinetic studies revealed mixed-type inhibition for compound <b>5b</b> (<i>K</i><sub><i>i</i></sub> = 10.03 µM, <i>K</i><sub><i>is</i></sub> = 36.16 µM), and molecular docking confirmed its stable interactions with AChE’s catalytic and peripheral anionic sites. These findings underscore the potential of cinnamoyl piperidinyl acetate derivatives as promising scaffolds for further optimization and development into effective AD therapeutics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Design and evaluation of substituted cinnamoyl piperidinyl acetate derivatives as potent cholinesterase inhibitors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月2日

查看全文
  • Maryam Esmkhani,
  • Shahrzad Javanshir,
  • Aida Iraji,
  • Mohammad Mahdavi

摘要

In the pursuit of therapeutic agents for Alzheimer’s disease (AD), this study employed a molecular hybridization strategy to design and synthesize substituted cinnamoyl piperidinyl acetates. A total of 17 novel derivatives were evaluated for their inhibitory effects against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), key enzymes implicated in AD pathogenesis. Notably, compound 5b, featuring a 2-chloro substitution, emerged as the most potent AChE inhibitor (IC50 = 19.74 ± 0.96 µM), while compound 5q, possessing a 4-ethoxy-3-methoxy moiety, demonstrated superior BChE inhibition (IC50 = 13.49 ± 0.44 µM). Kinetic studies revealed mixed-type inhibition for compound 5b (Ki = 10.03 µM, Kis = 36.16 µM), and molecular docking confirmed its stable interactions with AChE’s catalytic and peripheral anionic sites. These findings underscore the potential of cinnamoyl piperidinyl acetate derivatives as promising scaffolds for further optimization and development into effective AD therapeutics.